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Fig 1. CumI of Overall Infxns by treatment arm.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S50when comparing 2-year (yr) survival probabilities (Anasetti
et al, NEJM 2012;367:1487-96). Infection (infxn) was a pre-
speciﬁed secondary endpoint in this BMT CTN protocol,
sponsored by NHLBI and NCI. Moderate (mod) or more se-
vere (sev) infxns were reported on an event-driven Case
Report Form, excluding those that occurred pre-transplant.
Patients (pts) were censored at last follow up, relapse, 2nd
transplant, or 2 yrs after transplant, whichever came ﬁrst.
Among 551 pts enrolled at 48 centers between 01/2004 and
10/2009, 499 (249 of the BM arm and 250 on the PB arm) had
full audits of infxn data, accounting for 95% of transplanted
pts. Overall, 384 pts developed infxns of mod or greater
severity: 201 on the BM arm and 183 on the PB arm. Of 1347
infectious episodes (373 sev and 123 life-threatening/fatal
[LT/F]), 710 (53%) occurred on the BM arm and 637 (47%) on
the PB arm. Cumulative incidence (CumI) described the
proportion of pts developing at least one infxn, while
multivariate analyses examined the density of infxn epi-
sodes. Gray’s test for the CumI rates of infxns had p-value
0.013, with 2-yr rate 84.7% (95% conﬁdence interval [CI]:
79.6%, 89.8%) for the BM arm, vs. 79.7% (95%CI: 73.9%, 85.5%)
for the PB arm (Fig 1). Among 810 bacterial infxn episodes,
431 were on the BM arm and 379 on the PB arm, with a 2-yr
CumI of 72.1% and 62.9% respectively (Fig 2, p¼0.003). Of
these, 413 were bacterial bloodstream, 123 ClostridiumFig 2. CumI of Bacterial Infxns by treatment arm.difﬁcile, and 2 atypical mycobacterial infxns; these cate-
gories are not mutually exclusive. The Day 100 CumI of
bloodstream bacterial infxns was 44.8% (95%CI: 38.5%, 51.1%)
for the BM arm vs. 35.0% (95%CI: 28.9%, 41.1%) for the PB arm
(p¼0.027), possibly related to quicker neutrophil engraft-
ment using PB.
Infxn density was calculated as (# infxn events/100 pt days at
risk). The total infxn density was 0.67 for BM and 0.60 for PB
(P¼NS). The infxn density of bacterial infxns was 0.4 for both
arms. The infxn density for viral infxns was 0.2 in both arms.
The 2-yr CumI of CMVwas 25.9% (95%CI: 20.2%, 31.6%) for the
BM arm, vs. 24.4% (95%CI: 18.8%, 30.0%) for the PB arm
(p¼0.62). The infxn density for fungal/parasitic infxns was
0.04 and 0.05 for the BM arm and the PB arm, respectively.
The 2-yr CumI of 20 cases of aspergillosis was 3.9% (95%CI:
1.2%, 6.6%) for the BM arm, vs. 3.6% (95%CI: 1.0%, 6.2%) for the
PB arm (p¼0.811). The ongoingmorbidity andmortality from
infxns following transplantation remain frequent using
either graft source, with no observed differences in fungal or
viral infxn rates. The higher observed risks of bacterial infxns
using BM grafts may suggest either augmented prophylaxis
or heightened surveillance after these transplants.AUTOLOGOUS TRANSPLANTS
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Background: The likelihood of successful mobilization has
improved with the addition of Plerixafor to G-CSF in ASCT.
Due to its high cost, risk adapted algorithms were instituted
to identify patients who would beneﬁt from plerixafor.
Methods: The current algorithmwas instituted in December
2009. Mobilization commences with GCSF alone; plerixafor
is added if day 4 PBCD34 is<10/mL for single transplant,<20/
mL for multiple transplants, day 1 yield is <1.5 million CD34/
kg, or subsequent yield is < 0.5 million CD34/kg. Goal of
collection varied by disease and by number of intended
transplants (3-5 million CD34/kg/transplant). The results of
this mobilization strategy are presented here.
Results: We studied 1080 mobilizations in 1068 patients
using the current protocol between June 2010 and December
2013; 548MM (50%), 327 NHL (30%), 144 amyloidosis or light
chain deposition disease (AL/LCD; 13%) and 61 Hodgkin’s
(13%). Overall, 55.4% of patients required plerixafor (MM58%,
NHL 61%, AL/LCD 35%, HL 46%). The majority of patients
initiated plerixafor on day 4 for low PB CD34 count; 19%
started beyond 4 days for suboptimal CD34 collection. There
was no difference between the diagnoses in terms of the
need to initiate plerixafor for low PB CD34 or for suboptimal
CD34 collection. Median days of plerixafor was 2 (IQR 1-3);
42% and 22% required > 2 days and > 3 days, respectively.
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vs MM (41%), HL (40%) and AL/LCD (23%); p ¼ 0.004. The
median number of CD34 cells collected was 7.4 million/kg
(IQR 5.2- 9.9). Median CD34 collection was highest for MM
and AL/LCD, reﬂecting the practice to collect for more than
one transplant. Overall 9 (<1%) and 22 (2%) patients collected
< 2 million and < 2.5 million CD34 cells/kg, respectively.
More patients with NHL (4%) collected < 2.5 million/kg
compared with MM (1%), AL/LCD (2%) and HL (0%), p¼0.02.
The median number of days of apheresis was 2 (IQR 1-3) and
was higher in the NHL group (p¼0.002). The median CD34
collected per day was 3.6 million/ kg (IQR 2-5.8); higher in
MM and AL/LCD vs NHL and HL (p < 0.001). The median
CD34 collection was very similar for those patients getting
plerixafor versus those not requiring plerixafor (p¼0.26). The
median time to ANC and platelet engraftment were 14 days
(IQR 13-16) and 13 days (IQR 12-15), respectively. While
there was no difference in ANC engraftment, platelet
engraftment was longer among patients requiring plerixafor.
Conclusion: This data conﬁrms the effectiveness of this risk
adapted algorithm in over 1000 patients over 4 years. The
mobilization failure rate remains low. Approximately 45% of
patients did not require plerixafor, supporting the use of this
risk adapted algorithm to select appropriate patients who
require plerixafor.CLINICAL CELLULAR THERAPY32
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Cancer immunotherapy with NK cells is promising, but a
key challenge is the development of a method that can
consistently expand NK cells from a small fraction (w5%)
of unselected PBMCs to a therapeutically effective dose
while using “off the shelf” reagents, not requiring long-
term complex co-cultures, and with low doses of IL-2.
Methods that use feeder cells do expand NK cells, but
require complex procedures with prolonged ex vivo co-
culture with the feeder cells, are costly, are logistically
difﬁcult, and require subsequent administration of high
dose IL-2 for persistence after injection. We developed a
particle-based method to speciﬁcally expand cytotoxic NK
cells from unselected PBMCs. These particles, prepared
from plasma membrane (PM) of engineered K562 cells
that express cytokines such as IL-21 or IL-15 and 41BBL,
stimulate in vitro and in vivo expansion of NK cells. In vitro,
these PM-particles containing membrane bound IL-21
(PM21-particles) cause highly speciﬁc expansion of cyto-
toxic NK cells from unselected PBMCs by achieving >90%
NK cells in 14 days and 104 fold expansion of NK in 21
days. NK cell expansion is consistent with different prep-
arations of PM-particles or leukocyte sources, and the PM-
particles retain expansion efﬁcacy with -80C storage.
The PM21-particles also stimulate in vivo NK cell expan-
sion in NSG mice under ultralow IL-2 (1,000 U per injec-
tion, 3 x weekly). The efﬁcacy of ex vivo pre-activation
with PM21, prior to injection, was tested by injecting
PBMCs (2 x 106 PBMCs per mice, i.p., 6 mice per group),which were either activated in culture for two days with
200 mg/mL PM21 (PM21-PBMCs) or not pre-activated
(PBMCs), and then the abundance of hCD56+CD3- NK cells
and other hCD45+ lymphocytes were monitored in pe-
ripheral blood of mice. Clear efﬁcacy for pre-activation
was observed where the mice in the group given PM21-
PBMCs had 66 fold higher human NK (hNK) cells as
compared to the group injected with PBMCs. The efﬁcacy
of administering PM21-particles in vivo was examined also
where 2 x 106 PM21-PBMCs, were injected i.p. into mice (4
mice per group) that then received 0, 400, 800 or 1600 mg
of PM21 (i.p., 2 x weekly). The mice injected with 800 mg of
PM21 had the highest amount of hNK cells averaging
890,000 hNK/mL of mouse blood on day 16 and reaching
95  2% of total hCD45+ cells by day 12. By comparing the
averages between day 5 and 16 in this experimental group,
hNK cell increased a minimum of 390 fold in the mouse
blood. Furthermore, examination of organs from mice
sacriﬁced on day 16 after PM21-PBMC injection shows
signiﬁcant numbers of hNK cells in bone marrow, spleen,
lung, liver and brain. The extent of NK cells observed in
the peripheral blood (>50,000 NK cells/mL blood, 14 days
post injection) and biodistribution to sites of disease
would be relevant for clinical cancer treatment, and thus
shows that PM-particle technology could be suitable for
NK cell immunotherapy.33
CMVpp65-Speciﬁc T Cells Generated from Naïve T Cell
Populations Recognize Atypical but Not Canonical
Epitopes and May Be Protective In Vivo
Patrick J. Hanley 1, Jan Melenhorst 2, Sarah Nikiforow 3,
Phillip Scheinberg 4, Russell Cruz 5, Robert A. Krance 6,
Kathryn Leung 7, Caridad Martinez 7, Helen E. Heslop 8,
Cliona M. Rooney 8, A. John Barrett 9, Elizabeth J. Shpall 10,
Catherine M. Bollard 11. 1 CETI, Blood and Marrow
Transplantation, Children’s National Medical Center,
Washington, DC; 2Hematology, National Institutes of Health,
National Heart, Lung, and Blood Institute, Bethesda, MD;
3Hematologic Malignancies, Dana-Farber Cancer Institute,
Harvard Medical School, Boston, MA; 4 Antonio Ermirio de
Moraes Oncology Center, Hospital Beneﬁcência Portuguesa de
São Paulo, Sao Paulo, Brazil; 5 Sheikh Zayad Institute, Children’s
National Medical Center, Washington, DC; 6 Center for Cell and
Gene Therapy, Baylor College of Medicine, Houston Methodist
Hospital and Texas Children’s Hospital, Houston, TX; 7 Center
for Cell and Gene Therapy, Baylor College of Medicine, Texas
Children’s Hospital, Houston, TX; 8 Center for Cell and Gene
Therapy, Baylor College of Medicine, Texas Children’s Hospital,
Houston Methodist Hospital, Houston, TX; 9Hematology
Branch, National Heart, Lung, and Blood Institute, NIH,
Bethesda, MD; 10 Stem Cell Transplantation and Cellular
Therapy, The University of Texas MD Anderson Cancer Center,
Houston, TX; 11 Center for Cancer and Immunology Research,
Children’s National Medical Center, Washington, DC
Adoptive transfer of CMVpp65-speciﬁc T-cells (cCTL) from
CMV-seropositive (CMVpos) donors effectively restores
antiviral-immunity after stem cell transplantation. However,
the naïve T-cells in cord blood(CB) and adult CMV-serone-
gative(CMVneg) donors require different culture systems to
generate cCTL. With a novel GMP-applicable protocol we
have reliably generated cCTL from CB and CMVnegs and
found that of >20 T-cell lines, all recognized atypical epi-
topes of pp65. HLA-A2+ cCTL derived from naive T-cells
recognized novel pp65 epitopes (e.g. LQT) but not the
typical epitope NLV. Analysis of the avidity of naïve donor
